IVF Surrogacy — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

IVF surrogacy, more precisely termed gestational surrogacy or gestational carrier arrangement, is an assisted reproductive technology pathway in which embryos are created by in vitro fertilisation using eggs and sperm from the intended parents (or donors) and transferred to the uterus of a gestational carrier — the surrogate — who carries and delivers the pregnancy. The surrogate has no genetic relationship to the child because her own eggs are not used. This distinguishes gestational surrogacy from the now-rare traditional surrogacy, in which the surrogate's own oocytes are inseminated, creating a genetic link that raises significant ethical and legal complexities. Gestational surrogacy with IVF is indicated when the intended mother has no uterus or a non-functioning uterus, cannot carry a pregnancy safely due to medical conditions, has experienced recurrent implantation failure from severe uterine pathology, or when same-sex male couples or single males wish to have a genetically related child. The process requires medical, legal, and psychological coordination across multiple parties: the intended parents, the surrogate and her partner, fertility clinicians, embryologists, lawyers, and in many jurisdictions the courts. Legal frameworks governing surrogacy vary enormously worldwide, from fully regulated altruistic surrogacy (Canada, UK) to commercial surrogacy (some US states, Ukraine) to outright legal prohibition (many European countries, China). Independent legal advice for both intended parents and surrogate is mandatory before embryo transfer.

Gestational surrogacy is indicated for intended mothers or couples who cannot carry a pregnancy to term due to uterine factors, systemic medical conditions, or genetic considerations. Uterine indications include congenital absence of the uterus (Mayer-Rokitansky-Küster-Hauser syndrome — MRKH), prior hysterectomy for cancer or obstetric haemorrhage, and severe Asherman's syndrome (intrauterine adhesions obliterating the uterine cavity). Recurrent unexplained implantation failure after multiple IVF cycles in women whose embryo quality is confirmed good but where endometrial receptivity is suspected to be permanently impaired is another indication where surrogacy offers an alternative pathway. Medical contraindications to pregnancy that are life-threatening — severe pulmonary arterial hypertension (Eisenmenger syndrome), severe left ventricular dysfunction, significant renal failure, or prior uterine rupture with risk of recurrence — preclude safe gestation. Recurrent pregnancy loss from uterine causes unresponsive to hysteroscopic or medical treatment may prompt consideration of surrogacy. Same-sex male couples and single men who wish biological parenthood with the genetic contribution of one or both partners require a surrogate and, if using an egg donor, a donor egg IVF cycle. The intended mother's ovarian reserve and egg quality determine whether own eggs or donor eggs are used in the IVF component.

The process unfolds in five coordinated stages. Stage 1 — Medical and legal preparation: both intended mother and surrogate undergo comprehensive medical screening including uterine assessment by saline infusion sonography or hysteroscopy, infectious disease testing (HIV, hepatitis B and C, CMV, syphilis), and psychological assessment. A surrogacy agreement is signed by all parties before cycle commencement. Stage 2 — Ovarian stimulation and egg retrieval: the intended mother (or egg donor) receives a controlled ovarian hyperstimulation protocol using recombinant FSH and/or HMG injections for 10–14 days, monitored with serial transvaginal ultrasound follicle tracking and serum oestradiol measurements. A trigger injection (hCG or GnRH agonist) is given when lead follicles reach 17–20 mm. Transvaginal oocyte retrieval is performed under IV sedation and ultrasound guidance 36 hours after the trigger. Stage 3 — Fertilisation and embryo culture: retrieved oocytes are fertilised by intracytoplasmic sperm injection (ICSI) and cultured in sequential media to blastocyst stage (day 5–6). Preimplantation genetic testing (PGT-A for chromosomal aneuploidy screening) may be used to select euploid embryos. Stage 4 — Surrogate endometrial preparation: the surrogate's uterine lining is prepared with oestrogen (oral, transdermal, or vaginal) for 2–3 weeks to achieve an endometrial thickness above 7 mm with a trilaminar pattern, followed by progesterone supplementation (vaginal pessaries, intramuscular injections). Stage 5 — Embryo transfer: one blastocyst is transferred transcervically into the surrogate's prepared uterus under abdominal ultrasound guidance. A serum beta-hCG pregnancy test is performed 14 days after transfer.

Gestational surrogacy enables biological parenthood for individuals and couples for whom this would otherwise be medically impossible. For women with MRKH syndrome or those who have undergone hysterectomy, it is the only pathway to having a genetically related child. The ability to use own genetic material — eggs from the intended mother and sperm from the intended father — preserves the genetic parenthood bond that many couples consider fundamental. Modern embryo selection with preimplantation genetic testing significantly improves implantation and live birth rates and reduces the risk of chromosomal abnormality-related miscarriage in the surrogate, improving outcomes for both the surrogate and the intended parents. Live birth rates per gestational surrogacy transfer using young, proven surrogates with euploid blastocysts can reach 50–65% per transfer cycle and exceed 75–80% over multiple cycles, among the highest success rates achievable in assisted reproduction. For same-sex male couples, IVF surrogacy enables not only biological parenthood but also the use of reciprocal IVF where applicable. The surrogate's proven fertility (most agencies require prior successful pregnancy) and optimal uterine environment contribute to favourable outcomes that may exceed those achievable in the intended mother's own uterus where pathology exists.

Risks apply separately to the intended mother and the surrogate. For the intended mother or egg donor: the risks of controlled ovarian hyperstimulation include ovarian hyperstimulation syndrome (OHSS) in 1–2% of IVF cycles requiring hospitalisation, and the procedural risks of transvaginal oocyte retrieval (bleeding, infection, bowel or vessel injury — each below 0.1%). For the surrogate: she assumes all standard obstetric risks of pregnancy including miscarriage (10–15%), ectopic pregnancy (1–2%), gestational diabetes, pre-eclampsia, placenta praevia or accreta (increased risk in women with prior cesarean), preterm labour, and the risks of the birth itself. Multiple pregnancy risk (if more than one embryo is transferred) increases obstetric complications substantially; single embryo transfer is strongly recommended. Legal risks: surrogacy agreements are not enforceable in all jurisdictions, and parentage laws vary enormously — failure to obtain appropriate legal orders before or after birth can create profound legal uncertainty about parenthood. Emotional and relational risks require pre-cycle psychological counselling for intended parents, surrogate, and their partners to establish expectations and boundaries throughout a potentially lengthy and emotionally intense process lasting 12–18 months.

The intended mother's recovery from oocyte retrieval is typically 1–3 days. Mild pelvic discomfort and bloating are normal for 24–48 hours. If OHSS develops, management with oral fluids, analgesics, and monitoring of serum electrolytes, haematocrit, and urinary output is essential; severe OHSS requiring paracentesis or hospitalisation is rare with modern trigger protocols. The surrogate undergoes standard post-transfer care: two weeks of progesterone supplementation followed by a serum beta-hCG test. If pregnant, progesterone is continued until 10–12 weeks of gestation and routine antenatal care is organised with an obstetrician experienced in surrogate pregnancies. The intended parents maintain close communication with the surrogate throughout the pregnancy and are typically present at key antenatal milestones and the delivery itself. Legal parentage processes — parental orders, court orders, or birth certificate registration depending on jurisdiction — must be completed promptly after birth. Post-birth psychological support for all parties, including the surrogate's own family, should be available and planned during the agreement phase. If the first transfer cycle is unsuccessful, a frozen embryo transfer using remaining cryopreserved blastocysts can typically be scheduled 1–2 months later after a full review cycle.